Data on immunogenicity and reactogenicity to COVID-19 vaccination among 
patients receiving maintenance dialysis

Karakizlis, Hristos; Nahrgang, Christian; Strecker, Kevin; Chen, Jiangping; Aly, Mostafa; Slanina, Heiko; Schuettler, Christian G.; Esso, Isla; Wolter, Martin; Todorova, Darina; Jessen, Sonke; Adamik, Andrea; Ronco, Claudio; Seeger, Werner; Weimer, Rolf; Sester, Martina; Birk, Horst-Walter; Husain-Syed, Faeq

doi:10.1016/j.dib.2022.108271

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Data on immunogenicity and reactogenicity to COVID-19 vaccination among patients receiving maintenance dialysis

MPS-Authors

/persons/resource/persons224334

Seeger, Werner
Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Karakizlis, H., Nahrgang, C., Strecker, K., Chen, J., Aly, M., Slanina, H., et al. (2022). Data on immunogenicity and reactogenicity to COVID-19 vaccination among patients receiving maintenance dialysis. DATA IN BRIEF, 42: 108271. doi:10.1016/j.dib.2022.108271.

Cite as: https://hdl.handle.net/21.11116/0000-000A-A122-9

Abstract

Compared with the general population, patients receiving maintenance dialysis are at increased risk for morbidity and mortality associated with coronavirus disease 2019 (COVID-19). Currently, data on severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-specific immunity post -vaccination in patients on maintenance dialysis are scarce given that the effectiveness of the vaccines has not been ex-plicitly tested in this population due to their common exclu-sion from SARS-CoV-2 vaccination trials. We herein present data of the specific cellular (interferon-gamma and interleukin-2 ELISpot assays) and humoral immune responses (dot plot array and chemiluminescent microparticle immunoassay) at 4 weeks and 6 weeks following a single dose or a com-plete homologous dual dose SARS-CoV-2 vaccine regimen in 60 adult patients on maintenance dialysis (six with a his-tory of COVID-19). The data was produced in a framework of a project focused on a) quantifying the immune response after full vaccination, b) evaluating the short-term durabil-ity of immune response, and c) examining the reactogenicity of SARS-CoV-2 vaccine regimens in patients on maintenance dialysis. (C) 2022 The Author(s). Published by Elsevier Inc.